thumbnail

Hepatology

  0270-9139

 

 

Cơ quản chủ quản:  LIPPINCOTT WILLIAMS & WILKINS , WILEY , John Wiley and Sons Ltd

Lĩnh vực:
HepatologyMedicine (miscellaneous)

Các bài báo tiêu biểu

Design and validation of a histological scoring system for nonalcoholic fatty liver disease
Tập 41 Số 6 - Trang 1313-1321 - 2005
David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta, Cynthia Behling, Melissa J. Contos, Oscar W. Cummings, Linda D. Ferrell, Yao-Chang Liu, Michael Torbenson, Aynur Ünalp–Arida, Matthew M. Yeh, Arthur J. McCullough, Arun J. Sanyal
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Tập 64 Số 1 - Trang 73-84 - 2016
Zobair M. Younossi, Aaron B. Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver‐related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random‐effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10‐28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38‐61.20), type 2 diabetes (22.51%; 95% CI: 17.92‐27.89), hyperlipidemia (69.16%; 95% CI: 49.91‐83.46%), hypertension (39.34%; 95% CI: 33.15‐45.88), and metabolic syndrome (42.54%; 95% CI: 30.06‐56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69‐47.13) and 0.09 (95% CI: 0.06‐0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person‐years (range, 0.29‐0.66). Liver‐specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33‐1.77) and 11.77 per 1,000 person‐years (range, 7.10‐19.53) and 15.44 per 1,000 (range, 11.72‐20.34) and 25.56 per 1,000 person‐years (range, 6.29‐103.80). Incidence risk ratios for liver‐specific and overall mortality for NAFLD were 1.94 (range, 1.28‐2.92) and 1.05 (range, 0.70‐1.56). Conclusions: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2016;64:73–84)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Tập 67 Số 1 - Trang 328-357 - 2018
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary E. Rinella, Stephen A. Harrison, Elizabeth M. Brunt, Arun J. Sanyal
A model to predict survival in patients with end-stage liver disease
Tập 33 Số 2 - Trang 464-470 - 2001
Patrick S. Kamath, Russell H. Wiesner, Michael Malinchoc, Walter K. Kremers, Terry M. Therneau, Catherine L. Kosberg, Gennaro D’Amico, E. Rolland Dickson, M.B.A. W. Ray Kim
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Tập 43 Số 6 - Trang 1317-1325 - 2006
Richard K. Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Solà, Mendes Cassia Correa, Julio Montaner, Mark Sulkowski, Francesca J. Torriani, Doug Dieterich, David L. Thomas, Diethelm Messinger, Mark Nelson
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Tập 68 Số 2 - Trang 723-750 - 2018
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michaël Abécassis, Lewis R. Roberts, Julie K. Heimbach
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
Tập 40 Số 6 - Trang 1387-1395 - 2004
Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins, Pamela Nuremberg, Jay D. Horton, Jonathan C. Cohen, Scott M. Grundy, Helen H. Hobbs
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
Tập 1 Số 5 - Trang 431-435 - 1981
Robert G. Knodell, Kamal G. Ishak, William C. Black, Thomas S. Chen, Robert M. Craig, Neil Kaplowitz, Thomas W. Kiernan, Jerome S. Wollman
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Tập 55 Số 6 - Trang 2005-2023 - 2012
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Tập 45 Số 4 - Trang 846-854 - 2007
Paul Angulo, Jason M. Hui, Giulio Marchesini, E. Bugianesi, Jacob George, Geoffrey C. Farrell, Felicity Enders, Sushma Saksena, Alastair D. Burt, John P. Bida, Keith D. Lindor, Schuyler O. Sanderson, Marco Lenzi, Leon A. Adams, James G. Kench, Terry M. Therneau, Christopher P. Day